SBRT feasible for oligometastatic RCC

Affiliations

Comment

Peter Sidaway. Nat Rev Clin Oncol. 2022 Jan.

. 2022 Jan;19(1):6.

doi: 10.1038/s41571-021-00582-1.

No abstract available

Comment on

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Tang C, et al. Lancet Oncol. 2021 Dec;22(12):1732-1739. doi: 10.1016/S1470-2045(21)00528-3. Epub 2021 Oct 28. Lancet Oncol. 2021. PMID: 34717797 Free PMC article. Clinical Trial.

1. Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00528-3 (2021) - DOI - PubMed